Developing membrane-derived nanocarriers for ex vivo therapy of homologous breast cancer cells

Aim: The primary aim of this study was to develop biomimetic nanocarriers for specific homologous targeting of the anticancer drugs ammonium pyrrolidine dithiocarbamate (PDTC) and doxorubicin. Methods: Membranous nanovesicles were synthesized from a breast cancer cell line (MCF7) by syringe extrusion process and were loaded with PDTC and doxorubicin. Besides their abilities for self-homing, the drug loaded nanovesicles showed anti-cell proliferative effects via the generation of reactive oxygen species. Results: The nanovesicles demonstrated efficient internalization via homologous targeting. Delivery of PDTC showed a higher killing effect for homologous cell targeting than other cell types. Experimental results demonstrated increased antiproliferative potency of PDTC, which induced apoptosis via reactive oxygen species generation. Conclusion: The developed membrane-derived nanocarrier is an attractive biocompatible system for ex vivo targeted drug delivery.

Automated summary

This study aimed to develop biomimetic nanocarriers for specific homologous targeting of anticancer drugs PDTC and doxorubicin, showing efficient internalization and enhanced antiproliferative effects. The drug-loaded nanovesicles demonstrated higher killing effect for homologous cell targeting compared to other cell types, indicating increased antiproliferative potency and induction of apoptosis through ROS generation. The developed membrane-derived nanocarrier is a promising biocompatible system for ex vivo targeted drug delivery.